Compare Heron Therapeutics Inc (HRTX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Union Pacific Corporation — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Union Pacific Corporation trades at $293.64 (market cap $173.99B). The key difference: Union Pacific Corporation is far larger — about 2830.5× Heron Therapeutics Inc's market cap, and Union Pacific Corporation pays a 1.94% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | UNP | |
|---|---|---|
Market Cap | $61.47M | $173.99B |
Sector | Health | Industrials |
52-Week High | $1.49 | $307.32 |
52-Week Low | $0.32 | $214.91 |
Enterprise Value | $168.21M | $203.04B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Union Pacific (UNP) trades at $292.24, down 0.3% on the day, with a neutral technical signal. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised full-year guidance. Fundamentals remain robust with a net income margin of 28.85% and ROE of 39.7%, though valuation ratios like P/E of 23.71 are elevated. Recent news highlights a 3% dividend increase and ongoing merger developments with Norfolk Southern.
The outlook is positive, driven by service-led growth, pricing power, and efficiency gains. Key opportunities include domestic intermodal expansion and margin improvement. Risks involve high fuel costs, regulatory scrutiny of the merger, and economic sensitivity. Analyst consensus is bullish with a $334.33 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
